BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Down 3.7% Following Insider Selling

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRXGet Free Report) was down 3.7% during mid-day trading on Tuesday after an insider sold shares in the company. The company traded as low as $6.00 and last traded at $6.01. Approximately 600,286 shares changed hands during trading, a decline of 83% from the average daily volume of 3,433,885 shares. The stock had previously closed at $6.24.

Specifically, Director Alan G. Levin bought 7,861 shares of the stock in a transaction dated Thursday, May 30th. The shares were acquired at an average cost of $6.36 per share, with a total value of $49,995.96. Following the purchase, the director now directly owns 44,951 shares in the company, valued at approximately $285,888.36. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In related news, CFO Anthony Doyle purchased 36,300 shares of the firm’s stock in a transaction that occurred on Tuesday, May 14th. The shares were purchased at an average cost of $5.57 per share, with a total value of $202,191.00. Following the purchase, the chief financial officer now owns 266,744 shares of the company’s stock, valued at approximately $1,485,764.08. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Alan G. Levin purchased 7,861 shares of the firm’s stock in a transaction that occurred on Thursday, May 30th. The stock was bought at an average cost of $6.36 per share, for a total transaction of $49,995.96. Following the completion of the purchase, the director now directly owns 44,951 shares in the company, valued at approximately $285,888.36. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 103,601 shares of company stock valued at $596,338. Company insiders own 4.80% of the company’s stock.

Wall Street Analysts Forecast Growth

BCRX has been the subject of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th. JMP Securities increased their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “market outperform” rating in a report on Tuesday, May 7th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $12.00 price objective on shares of BioCryst Pharmaceuticals in a report on Tuesday, May 7th. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $14.00.

Read Our Latest Stock Report on BioCryst Pharmaceuticals

BioCryst Pharmaceuticals Price Performance

The company’s fifty day moving average is $5.52 and its two-hundred day moving average is $5.61.

BioCryst Pharmaceuticals (NASDAQ:BCRXGet Free Report) last posted its quarterly earnings results on Monday, May 6th. The biotechnology company reported ($0.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.06. The business had revenue of $92.80 million during the quarter, compared to analyst estimates of $85.62 million. During the same quarter in the prior year, the business earned ($0.28) earnings per share. The firm’s quarterly revenue was up 34.9% on a year-over-year basis. Equities analysts expect that BioCryst Pharmaceuticals, Inc. will post -0.66 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Quarry LP acquired a new position in shares of BioCryst Pharmaceuticals during the 4th quarter worth approximately $54,000. Seven Eight Capital LP acquired a new position in BioCryst Pharmaceuticals in the 1st quarter valued at $57,000. Natixis raised its holdings in BioCryst Pharmaceuticals by 400.6% in the 1st quarter. Natixis now owns 11,684 shares of the biotechnology company’s stock valued at $59,000 after acquiring an additional 9,350 shares during the last quarter. Tower Research Capital LLC TRC raised its holdings in BioCryst Pharmaceuticals by 131.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,420 shares of the biotechnology company’s stock valued at $62,000 after acquiring an additional 5,912 shares during the last quarter. Finally, JGP Global Gestao de Recursos Ltda. purchased a new stake in shares of BioCryst Pharmaceuticals during the 4th quarter valued at $64,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

(Get Free Report)

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.

Further Reading

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.